Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Century Therapeutics Inc (IPSC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.67+9.87%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IPSC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Submit CNTY-813 IND by Q4 2026 | Management aims to submit the CNTY-813 IND by Q4 2026. | Intact | IND submission delayed beyond 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “"We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.” “Our recent pre-IND meeting with the FDA builds on that progress yielding alignment with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission on track for the fourth quarter of 2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotech, so its multi-year view depends on advancing its programs rather than established earnings. The thesis is in a watch state: stated development milestones remain on track, but recent performance is below its industry cohort.
The available valuation signal describes IPSC as cheap versus peers, but confidence in that comparison is low. With the business still loss-making, the evidence does not show clearly what growth or clinical success the market already assumes.
Near term, management says CNTY-813’s regulatory filing and CNTY-308’s trial initiation remain on track; initial CNTY-813 clinical data is expected in the second half of 2027. Cash declined from $217.0 million at 2026-Q1 to $197.2 million at 2026-Q2, with runway estimated into 1Q 2029, while recent results include an August earnings miss and a September CEO transition. The next results carry elevated miss risk, and a guidance cut would be a meaningful setback.
The multi-year thesis hinges on meeting development milestones and maintaining the stated cash runway as the programs advance. Near term, weaker jobs data could add pressure to cyclical and healthcare names, while continued strength from sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, IPSC remains a milestone-driven, loss-making biotech with encouraging stated program progress but meaningful execution and financial risk. The evidence supports watching whether management delivers on its timelines and runway plan. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce losses and improve EPS | A supporting condition in Century Therapeutics Inc's published investment case. The stated target is EPS loss narrows to better than -$0.40 per share. | Broken | EPS loss worsens beyond -$0.50 per share in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain revenue at approximately $109 million | A primary condition in Century Therapeutics Inc's published investment case. The stated target is Revenue >= $100 million annually. | Under Pressure | Revenue falls below $100 million in any quarter | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $100 million annually. Target period is not explicitly aligned with this observation. Aug 12, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.44 → $-0.45 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-25 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-26 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-27 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-28 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-29 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-07-30 | $-0.46 | $0 | 4 / 5 |
| 2026-07-31 | $-0.46 | $0 | 4 / 5 |
| 2026-08-01 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-02 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-03 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-04 | $-0.46 | $0 | 4 / 5 |
| 2026-08-05 | $-0.46 | $0 | 4 / 5 |
| 2026-08-06 | $-0.46 | $0 | 4 / 5 |
| 2026-08-07 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-08 | $-0.46 | $0 | 4 / 5 |
| 2026-08-09 | $-0.46 | $0 | 4 / 5 |
| 2026-08-10 | $-0.46 | $0 | 4 / 5 |
| 2026-08-12 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-13 | $-0.46 | $0 | 4 / 5 |
| 2026-08-14 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-15 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-16 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-17 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-18 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-19 | $-0.44 | $3,735,000 | 3 / 5 |
| 2026-08-20 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-21 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-22 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-23 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-24 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-25 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-26 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-27 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-28 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-29 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-30 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-08-31 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-01 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-02 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-03 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-04 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-05 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-06 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-07 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-08 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-09 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-10 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-11 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-12 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-13 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-14 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-15 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-16 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-17 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-18 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-19 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-20 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-21 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-22 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-23 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-24 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-25 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-26 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-27 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-28 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-29 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-09-30 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-01 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-02 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-03 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-04 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-05 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-06 | $-0.45 | $3,735,000 | 3 / 4 |
| 2026-10-07 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-08 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-09 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-10 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-11 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-12 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-13 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-14 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-15 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-16 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-17 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-18 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-19 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-20 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-21 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-22 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-23 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-24 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-25 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-26 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-27 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-28 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-29 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-30 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-10-31 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-11-01 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-11-02 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-11-03 | $-0.45 | $3,735,000 | 3 / 5 |
| 2026-11-04 | $-0.45 | $3,735,000 | 3 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.